The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial.

Published

Journal Article

In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53 years old. Subjects were randomized to HC + placebo, Mg + placebo, HC + Mg, or placebo + placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8 weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.

Full Text

Duke Authors

Cited Authors

  • Wang, W; Brugnara, C; Snyder, C; Wynn, L; Rogers, Z; Kalinyak, K; Brown, C; Qureshi, A; Bigelow, C; Neumayr, L; Smith-Whitley, K; Chui, DHK; Delahunty, M; Woolson, R; Steinberg, M; Telen, M; Kesler, K

Published Date

  • March 2011

Published In

Volume / Issue

  • 152 / 6

Start / End Page

  • 771 - 776

PubMed ID

  • 21275961

Pubmed Central ID

  • 21275961

Electronic International Standard Serial Number (EISSN)

  • 1365-2141

Digital Object Identifier (DOI)

  • 10.1111/j.1365-2141.2010.08523.x

Language

  • eng

Conference Location

  • England